ישראל - עברית - Ministry of Health

inovamed ltd - mycophenolic acid - טבליות שחרור מושהה - mycophenolic acid 180 mg - mycophenolic acid

ישראל - עברית - Ministry of Health

inovamed ltd - mycophenolic acid as - טבליות שחרור מושהה - mycophenolic acid as 360 mg - mycophenolic acid

ישראל - עברית - Ministry of Health

beit-erez havat milatin ltd - metronidazole; spiramycin - טבליה - metronidazole 125 mg; spiramycin 750000 iu

ישראל - עברית - Ministry of Health

rafa laboratories ltd - netupitant; palonosetron as hydrochloride - קפסולות - netupitant 300 mg; palonosetron as hydrochloride 0.50 mg - palonosetron, combinations

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - glecaprevir; pibrentasvir - טבליות מצופות פילם - pibrentasvir 40 mg; glecaprevir 100 mg - glecaprevir and pibrentasvir

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - glecaprevir; pibrentasvir - טבליות מצופות פילם - pibrentasvir 40 mg; glecaprevir 100 mg - glecaprevir and pibrentasvir

ישראל - עברית - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

ישראל - עברית - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

ישראל - עברית - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.